Ipilimumab and Imatinib Mesylate in Advanced Cancer
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate
in treating patients with solid tumors that have spread to other places in the body or cannot
be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Imatinib mesylate may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving ipilimumab and imatinib mesylate may work better
in treating patients with solid tumors.